Firma Nomad Bioscience, Autor bei Presse-Blog

NOMAD BIOSCIENCE Extends and Broadens Its Agreements with Research and Commercial Growers, Spain, to Conduct Pilot Field and Greenhouse Trials Aimed at Industrial Manufacturing of Its Protein Products

6. Juni 20236. Juni 2023 Firma Nomad BioscienceBiotechnikagri, clinical, ctaex, del, Exploration, extremadura, ibmcp, market, nomads, olive, olivos, origin, tabacoex, thaumatin, with

NOMAD BIOSCIENCE GmbH, Munich, Germany (“NOMAD”) is pleased to announce that it has renewed and extended its development and production agreements with CENTRO TECNOLOGICO NACIONAL AGROALIMENTARIO EXTREMADURA (“CTAEX”), Badajoz, TABACOEX cooperative, Rosalejo, and OLIVOS DE BADAJOZ, Badajoz in Extremadura region Mehr

Nomad Bioscience and Fraunhofer Institute of Cell Therapy and Immunology Extend their Research and Development Agreement

24. Januar 202324. Januar 2023 Firma Nomad BioscienceBiotechnikassay, cell, clinical, drugs, fraunhofer, medical, new, nomad, nomads, pathology, production, research, therapy, vaccines, with

Nomad Bioscience GmbH, Munich, Germany (“NOMAD”) is pleased to announce that the Company has extended its research and development agreement (“Agreement”) with the Fraunhofer Institute of Cell Therapy and Immunology, Leipzig/Halle, Germany (“FRAUNHOFER”) that covers multiple areas of research and Mehr

NOMAD Bioscience receives patents in Japan and Australia for its antibacterials Salmocins

11. Oktober 202211. Oktober 2022 Firma Nomad BioscienceBiotechnikbacteriocins, Biotech, clinical, company, enterica, food, market, medical, nomad, nomads, research, salmocins, salmonella, veterinary, with

NOMAD Bioscience GmbH has announced that the patent offices of Japan and Australia have issued the decisions to grant patents for NOMAD’s patent applications ‘Bacteriocins for the control of Salmonella enterica, JP2019-551665 and AU2018239310.The patents cover NOMAD’s Salmocins, non-antibiotic antibacterial proteins Mehr

NOMADS UAB, Lithuania Published a Milestone Research Paper Describing its Chimeric Bacteriocins for Control of Multidrug-Resistant Pseudomonas

20. April 2022 Firma Nomad BioscienceBiotechnikaeruginosa, bacteriocins, biosciences, chimera, domain, medical, new, nomad, nomads, paper, pseudomonas, pyocins, rep, research, with

NOMADS UAB, Lithuania, NOMAD Bioscience’s wholly owned subsidiary, announces publication in the Nature group journal Scientific Reports (Š. Paškevičius, V. Dapkutė, A. Misiūnas, M. Balzaris, P. Thommes, A. Sattar, Y. Gleba and A. Ražanskienė, “Chimeric bacteriocin S5-PmnH engineered by domain Mehr

NOMAD BIOSCIENCE Broadens Its Agreements with Research and Commercial Growers, Spain, to Conduct Pilot Field and Greenhouse Trials Aimed at Industrial Manufacturing of Its Protein Products

21. März 202221. März 2022 Firma Nomad BioscienceBiotechnikcell, clinical, ctaex, del, Exploration, extremadura, ibmcp, market, nomad, nomads, olive, origin, smart, thaumatin, with

NOMAD BIOSCIENCE GmbH, Munich, Germany (“NOMAD”) is pleased to announce that it has renewed and extended its development and production agreements with CENTRO TECNOLOGICO NACIONAL AGROALIMENTARIO EXTREMADURA (“CTAEX”), Badajoz, Spain, TABACOEX cooperative, Rosalejo, and OLIVOS DE BADAJOZ cooperative, Badajoz in Mehr

NOMAD Bioscience Receives GRAS Regulatory Recognition by FEMA for Its Plant-Made Natural Thaumatin II as a Flavour Modifier/Enhancer

17. März 202217. März 2022 Firma Nomad BioscienceBiotechnikcaloric, FDA, food, foods, ingredients, market, new, nomad, nomads, ppm, source, sweeteners, thaumatin, thaumatins, with

NOMAD Bioscience GmbH received a formal GRAS recognition letter from the Flavor and Extract Manufacturers Association (FEMA) in response to NOMAD’s GRAS application describing use of plant-expressed Thaumatin II as a flavour modifier/enhancer (FEMA GRAS 5010). FEMA’s expert panel has Mehr

Prof. Dr. Yuri (Jurijus) Gleba, CEO and majority shareholder of NOMAD Bioscience has supported Ukrainian Army by donating 100 thousand Euro to reinforce the defense against Russian aggression

15. März 202215. März 2022 Firma Nomad BioscienceFirmenintern??future, armed, bioscience, biotechnology, company, defense??, entrepreneur, german, nomad, other, prof, refugees, russian, thousand, ukraine

Prof. Dr. Yuri (Jurijus) Gleba, renown scientist and entrepreneur, CEO and major shareholder of Nomad Bioscience GmbH, a German biotechnology company, has donated 100 thousand Euro to the Armed Forces of Ukraine to support the defense against Russian aggression. Prof. Mehr

NOMAD Bioscience Extends Its GRAS Regulatory Clearance In USA For Plant-Made Natural Thaumatin II As Sweetener, Amendment GRN 910S

24. Februar 202224. Februar 2022 Firma Nomad BioscienceBiotechnik910s, caloric, drug, food, ingredients, market, nomad, nomads, production, protein, source, sugar, sweeteners, thaumatin, thaumatins

NOMAD Bioscience received a formal ‘no questions’ letter from the US Food and Drug Administration (FDA) in response to NOMAD’s GRAS notice amendment GRN 910S describing broader use of plant-produced Thaumatin II as sweetener. Thaumatin II is natural noncaloric high Mehr

Nomad Bioscience and Fraunhofer Institute of Cell Therapy and Immunology Extend and Broaden their Research and Development Agreement

4. Januar 20224. Januar 2022 Firma Nomad BioscienceBiotechnikassay, cell, drugs, fraunhofer, influenza, market, nomad, nomads, pathology, production, pseudomonas, research, therapy, vaccines, with

Nomad Bioscience GmbH, Munich, Germany (“NOMAD”) is pleased to announce that the Company has extended and broadened its research and development agreement (“Agreement”) with the Fraunhofer Institute of Cell Therapy and Immunology, Leipzig/Halle, Germany (“FRAUNHOFER”) that covers multiple areas of Mehr

NOMAD Bioscience Receives Notice of Allowance from USPTO for Its Patent Application ‚Bacteriocins for control of Salmonella enterica‘

1. September 20212. September 2021 Firma Nomad BioscienceBiotechnikbacteriocins, clinical, colicins, enterica, medical, nomad, nomads, pseudomonas, registrations, research, salmocins, salmonella, solutions, veterinary, with

NOMAD has announced that the United States’ Patent and Trademark Office (USPTO) has issued the "Notice of Allowance" for the NOMAD’s patent application “Bacteriocins for control of Salmonella enterica”, U.S. Appl. No. 16/577,484. All filed claims of the application necessary Mehr

Autor: Firma Nomad Bioscience